Fluvoxamine-induced neuroleptic malignant syndrome

Neuroleptic malignant syndrome (NMS) is an uncommon but life-threatening idiosyncratic drug reaction that occurs following neuroleptic drug exposure. The estimated incidence of NMS is though very low, resulting mortality rates range between 4% and 30%. There is increasing evidence that "Atypica...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the scientific society (Belgaum) Vol. 44; no. 3; pp. 161 - 162
Main Authors:	Bellad, Adarsh, Koparde, Vinayak, Patil, Sandeep, Chate, Sameeran
Format:	Journal Article
Language:	English
Published:	Mumbai Wolters Kluwer India Pvt. Ltd 01-09-2017 Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd Wolters Kluwer Medknow Publications
Subjects:	Adverse drug reactions Antidepressants Antipsychotic agents Antipsychotics Blood pressure Cardiac arrhythmia Complications and side effects Consent Fluvoxamine Hypertension Intensive care Laboratories Metabolism Neuroleptic malignant syndrome Neurotoxicity Obsessive compulsive disorder Pathogenesis Patients Psychiatry Psychotropic drugs Serotonin Serotonin uptake inhibitors SSRIs Urine Adverse drug reactions fluvoxamine SSRIs neuroleptic malignant syndrome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Neuroleptic malignant syndrome (NMS) is an uncommon but life-threatening idiosyncratic drug reaction that occurs following neuroleptic drug exposure. The estimated incidence of NMS is though very low, resulting mortality rates range between 4% and 30%. There is increasing evidence that "Atypical" antipsychotics are associated with NMS that has a different character. NMS occurring with selective serotonin reuptake inhibitors' use is extremely rare, and it should be differentiated from serotonin syndrome. Here, we report a rare case of NMS induced by fluvoxamine.
ISSN:	0974-5009 2278-7127
DOI:	10.4103/jss.JSS_28_17